Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.20
+2.6%		$1.05
$0.74
▼
$1.74
$37.73M0.26145,244 shs115,006 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$4.18
+3.5%		$3.73
$2.60
▼
$14.68
$35.15M1.21146,503 shs59,410 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$5.77
+0.2%		$6.06
$8.50
▼
$23.00
$36.07MN/A37,647 shs2,116 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.36
-5.8%		$0.65
$0.35
▼
$95.50
$7.45M-2.43.69 million shs1.06 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
+2.56%+1.69%+16.50%+14.29%-24.05%
Briacell Therap stock logo
BCTX
Briacell Therap
+3.47%+0.48%+17.09%+19.77%-68.04%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-7.61%-15.77%-29.12%-56.62%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-5.84%-19.48%-28.54%-75.99%-99.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.20
+2.6%		$1.05
$0.74
▼
$1.74
$37.73M0.26145,244 shs115,006 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$4.18
+3.5%		$3.73
$2.60
▼
$14.68
$35.15M1.21146,503 shs59,410 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$5.77
+0.2%		$6.06
$8.50
▼
$23.00
$36.07MN/A37,647 shs2,116 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.36
-5.8%		$0.65
$0.35
▼
$95.50
$7.45M-2.43.69 million shs1.06 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
+2.56%+1.69%+16.50%+14.29%-24.05%
Briacell Therap stock logo
BCTX
Briacell Therap
+3.47%+0.48%+17.09%+19.77%-68.04%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-7.61%-15.77%-29.12%-56.62%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-5.84%-19.48%-28.54%-75.99%-99.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$5.00316.67% Upside
Briacell Therap stock logo
BCTX
Briacell Therap
1.00
SellN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest KALA, IZTC, BCTX, and ATNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Briacell Therap stock logo
BCTX
Briacell Therap
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M1.08N/AN/A$1.31 per share0.92
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A$9.20 per shareN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/A$12.56 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.36N/AN/AN/AN/A-100.85%-47.89%N/A
Briacell Therap stock logo
BCTX
Briacell Therap
-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$26.98M-$31.96N/AN/AN/AN/A-222.35%-70.23%11/10/2026 (Estimated)

Latest KALA, IZTC, BCTX, and ATNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$6.00-$21.32-$15.32-$21.32$25.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
7.07
7.07
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/A
6.88
6.88

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.60%
Briacell Therap stock logo
BCTX
Briacell Therap
0.74%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
2.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2531.44 million29.32 millionOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
48.70 million8.64 millionNo Data
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
619.34 million18.91 millionNot Optionable

Recent News About These Companies

KALA BIO stock targets telehealth expansion with a USD 15.00 million LOI
September 30, 2026  |  ad-hoc-news.deA
KALA Bio Signs LOI To Acquire Nationwide Telehealth Platform; Shares Rise
September 30, 2026  |  rttnews.comhttps://www.rttnews.com/3695210/kala-bio-signs-loi-to-acquire-nationwide-telehealth-platform-shares-rise.aspx
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
September 29, 2026  |  newsfilecorp.comN
Kala Bio, Inc. And Virotek Inc. Sign Letter Of Intent With U.S. DNA Testing Platform To Resell Virotek Inc.'s Suite Of Genetic Testing Products
September 25, 2026  |  marketscreener.comM
Kala Bio, Inc. und Virotek Inc. unterzeichnen Absichtserklärung mit einer US-amerikanischen DNA-Testplattform zum Weiterverkauf der genetischen Testproduktpalette von Virotek Inc.
September 25, 2026  |  de.marketscreener.comD
Kala Bio And Virotek Sign LOI To Expand Genetic Testing Distribution
September 24, 2026  |  rttnews.comhttps://www.rttnews.com/3693677/kala-bio-and-virotek-sign-loi-to-expand-genetic-testing-distribution.aspx
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368214/0/en/kala-bio-and-virotek-sign-letter-of-intent-with-u-s-dna-testing-platform-to-resell-virotek-s-suite-of-genetic-testing-products.html
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3363873/0/en/kala-bio-adds-healthcare-operator-yenvy-truong-to-advisory-team.html
Kala Bio signs exclusive US distribution agreement for Virotek ophthalmology genetic tests
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/kala-bio-signs-exclusive-us-distribution-agreement-for-virotek-ophthalmology-genetic-tests/ar-AA2bvf5Z
KALA stock falls after reverse split as Kala Bio pursues ophthalmology partnerships
September 3, 2026  |  ad-hoc-news.deA
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355914/0/en/kala-bio-and-virotek-finalize-definitive-agreement-establishing-exclusive-u-s-distribution-partnership-for-ophthalmology-genetic-testing-program.html
KALA BIO, Inc. (KALA) Stock Price, News, Quote & History - Yahoo Finance
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/KALA/latest-news/
Kala Bio Signs LOI With Virotek For Exclusive U.S. Distribution; Stock Down
September 1, 2026  |  rttnews.comhttps://www.rttnews.com/3687576/kala-bio-signs-loi-with-virotek-for-exclusive-u-s-distribution-stock-down.aspx
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/kala-bio-targets-near-term-150548883.html
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354030/0/en/kala-bio-and-virotek-announce-letter-of-intent-to-establish-an-exclusive-u-s-distribution-partnership-for-ophthalmology-genetic-testing-program.html
KALA BIO Announces Brief Delay in Quarterly Filing
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kala-bio-announces-brief-delay-in-quarterly-filing?utm_source=marketbeat.com&utm_medium=referral
KALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 mark
May 8, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/kala-stock-hits-record-low-firm-announces-reverse-split-after-shares-fail-to-surpass-the-1-mark/ar-AA22CD5B
KALA BIO Announces Reverse Stock Split
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290093/0/en/kala-bio-announces-reverse-stock-split.html
How smart traders spot penny stock breakouts fast
May 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/how-smart-traders-spot-penny-stock-breakouts-fast/gm-GM067D14C2
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3277779/0/en/kala-bio-celebrates-trump-executive-order-as-game-changer-for-psychedelic-medicine.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.20 +0.03 (+2.56%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$1.21 +0.01 (+0.83%)
As of 10/5/2026 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$4.18 +0.14 (+3.47%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$4.12 -0.05 (-1.32%)
As of 10/5/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$5.77 +0.01 (+0.17%)
As of 10/2/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$0.36 -0.02 (-5.84%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-0.69%)
As of 10/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas